Ariad Pharmaceuticals Inc fka ARIA

[LUMA14]

Positive Phase 2 Study Results Reported for Brigatinib in NSCLC Patients

Link to article

“Whether this is a reflection of broader suppression of potential resistance mutations, or its effects on protecting the central nervous system, or both, requires further investigation, but by itself these progression-free survival data should be very encouraging for physicians and patients alike,” he said.

Camidge said the data supports pursuing brigatinib both post-Xalkori and in the ongoing ALTA 1L study, “which aims to assess its potential in the ALK treatment-naive setting.”

And the story is on the way to the physicians...
Domination of 2nd/3rd line after approval Q1/2017

40 locations ALTA-1L up to now.
ALTA-1L Study: A Phase 3 Study of Brigatinib Versus Crizotinib in ALK-positive Advanced Non-Small Cell Lung Cancer Patients (ALTA-1L)
Great opportunity to use Brigatinib without approval.
Great chance for fitting patients world wide.